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Scaling of a microphysiological system (MPS) or physiome-on-a-chip is arguably two interrelated, modeling-based activities:
on-platform scaling and in vitro-in vivo translation. This dual approach reduces the need to perfectly rescale and mimic in
vivo physiology, an aspiration that is both extremely challenging and not substantively meaningful because of uncertain
relevance of any specific physiological condition. Accordingly, this perspective offers a tractable approach for designing
interacting MPSs and relating in vitro results to analogous context in vivo.
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Significant efforts to develop single and interacting micro-
physiological systems (MPSs)1—engineered, in vitro human
tissues that mimic human physiology—have been underway
for several decades. Sometimes called “body-on-a-chip,”
we prefer “physiome-on-a-chip” to emphasize function
rather than literal reproduction of the body. Interest has
accelerated in response to advances in culture of human
primary cells and induced pluripotent stem cells, tissue
engineering entering the clinic, and the ongoing need for
improved preclinical-to-clinical translation in drug develop-
ment. Serious attempts at integrating these physiologically
representative MPSs on a single platform are just recently
underway.1
A fundamental challenge is “scaling”—the specification of
tissue dimensions and operating conditions to capture
desired physiology and enable studies of interest. Several
approaches include allometric scaling, histological sections,
and functional scaling.2 Currently, the most favored is func-
tional scaling—designing the MPS to reproduce tissue or
organ functions, such as metabolism rate, blood residence
time, or oxygen transport.1–3 Exactly which functions should
be recapitulated is a matter of planned platform use and a
researcher’s vision. A frequent conception is that proper
scaling will sufficiently reproduce in vivo physiology such
that “the same” measurements of response will be obtained
in vitro as in vivo without further translational analysis.
Our “physiome-on-a-chip” experience has driven us to
pragmatically modify our objective to developing MPSs and
platforms from which results are understandable within the
platform’s context and are translatable to in vivo physiology
using mathematical models. Practically, this splits scaling
into two interrelated activities: “on-platform scaling,” the
specification of MPS and platform characteristics and oper-
ating parameters, and in vitro-in vivo translation (IVIVT), the
process of relating platform results to in vivo physiology
(Figure 1). On-platform scaling must reproduce biological
functions of a tissue well enough to allow observation and
measurement, but not identically to an organ. IVIVT then
uses mathematical models to relate in vitro results to the
analogous in vivo context, preferably on a mechanistic,
not just correlative or extrapolative, basis. Relevant in vitro
to in vivo differences are accounted for in this process. Ap-
proaches to IVIVT depend on on-platform scaling choices,
so while their aims differ (design vs. translation) both must
be considered throughout platform development and may
well use the same mathematical models.
ON-PLATFORM SCALING
Because the purpose of MPS development is to create bet-
ter in vitro models of human function, scaling based on
functions rather than dimensions is sensible. It begs the
question, however, of which functions take precedence,
especially in multi-MPS platforms. Although a common
default has been to select an organ’s most defining func-
tions, an alternate is to consider a function’s purpose on
the platform: does it provide a crucial operational or regula-
tory role (“maintenance functions”), or simply an indication
of MPS activity (“output functions”). For example, if a lung
MPS is responsible for oxygenating a platform, then its oxy-
gen transport properties and operating conditions (e.g., sur-
face area, diffusivity, and oxygen concentration) must be
designed accordingly, but if oxygen transport is simply an
indicator of MPS health, then design need only enable
proper measurement. The practical implications are that
design requirements for maintenance and output purposes
will frequently be different, and, interestingly, there is no
single correct scaling for a given function.
Another consideration is that platforms must recapitulate
multiple functions simultaneously, so a systemic scaling
approach using multivariate optimization is highly desirable.
Such on-platform scaling must enable desired functions
while accounting for relative tissue and medium dimensions,
dynamics, MPS-MPS interactions (e.g., via released media-
tors or drug metabolites), and desired research applications.
1Stokes Consulting, Redwood City, California, USA; 2Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
*Correspondence: CL Stokes (stokes@cindystokes.com)
Received 5 June 2015; accepted 11 September 2015; published online on 10 October 2015. doi:10.1002/psp4.12042
Citation: CPT Pharmacometrics Syst. Pharmacol. (2015) 4, 559–562; doi:10.1002/psp4.12042
VC 2015 ASCPT All rights reserved
We recently attempted this to revise a liver MPS (compris-
ing human hepatocytes and Kupffer cells in a 3D structure)
to improve pharmacokinetic (PK) measurability and phar-
macodynamic (PD) response. We wished to simultaneously
attain certain biological function (e.g., viability, oxygen utili-
zation, cytochrome P450 activity) and PK and PD
responses (e.g., drug and hormone metabolism, autocrine
activity, inflammation), while constrained by an established
tissue mass and requirements for nutrients, oxygenation,
and medium change interval. Design parameters included
medium volume relative to tissue mass, medium circulation
rate, and surface area for oxygen exchange. With this prob-
lem definition, we utilized a systems pharmacology mathe-
matical model including flow; kinetics of drugs, hormones,
and tissue-produced factors; oxygen utilization; and nutrient
requirements to identify ranges of design parameter values
that best met functional and operational requirements.
Although not all features were simultaneously feasible with
current hardware, the analysis provides a basis for future
design iterations to better accommodate all constraints.
Extension of this approach to multi-MPS platforms should
be reasonably straightforward using appropriate systems
pharmacology models4 to identify key modulators of basic
biology, PK and PD within desired operational schemas of
an MPS or multi-MPS platform. Such a functional approach
to on-platform scaling requires careful consideration of both
organ functions of interest and desired platform uses; differ-
ent uses may result in differently specified platforms.
IVIVT
Although recapitulating human organ physiology is a key
MPS goal, even ideally designed multi-MPS platforms can-
not represent the complete human context. Additional inter-
pretive steps—IVIVT—will be needed to predict human
responses from platform results to account for missing
organs and functions, organ and media size mismatches,
and drug exposure differences. Especially challenging will
be accounting for variations in physiological and pathologi-
cal states because human responses frequently vary due
to exercise, feeding, and rest; acute and chronic illnesses;
and aging.
On-platform scaling of MPSs is still an immature endeavor
and IVIVT even more so. Nonetheless, it is useful to con-
sider what will be required for MPSs to be more predictive
than existing preclinical models. Where substantial mecha-
nistic understanding exists, such as for PK and absorption,
distribution, metabolism, and excretion, translational mathe-
matical models will likely suffice. A critical consideration is
what metrics to translate; quantifying fundamental aspects of
biological functions rather than representing them by phe-
nomenological parameters seems necessary. For example,
our measurements of typical PK parameters (drug half-life,
clearance) in our liver MPS and multi-MPS platforms are dif-
ferent than in humans because they reflect major system
characteristics: our MPS medium-to-tissue ratio is larger
than blood-to-liver ratio in vivo so drug disappearance is
slower on-platform for the same initial drug concentration. To
alleviate this, we are developing more mechanistic models
for both in vitro and in vivo systems that isolate elimination
processes from system characteristics, thereby defining
tissue-specific elimination rate parameters. Such parameters
should be better comparators from in vitro and in vivo, with a
major outstanding challenge being measurement or deriva-
tion of them in in vivo systems. Similar approaches should
also hold for IVIVT of PD, toxicodynamics, and therapeutic
window in which enough mechanistic information exists to
separate mechanism from system context.
Practically, validation of an IVIVT approach will require in
vivo data. For pharmacological uses, this implies focusing
on drugs already studied in humans, as done for develop-
ment of liver microsomes and hepatocyte cultures as
predictive systems for PK.5 Nonetheless, research on fun-
damental biology in MPSs will be fruitful regardless of
extensive IVIVT validation.
In contrast to PK and absorption, distribution, metabo-
lism, and excretion, areas of lesser understood biology, dis-
ease processes, and drug targets may require significant
rethinking of how biology itself is observed and inter-
preted long before translational work is attempted. Even for
in vitro studies, the systems biology field has learned that
“information-centric” rather than “mechanism-centric” mod-
els are generally required to predict complex cell behavioral
responses. For such behaviors as proliferation, migration,
and cytokine production, the dynamics of multiple signaling
pathways must be integrated, but insufficient understanding
of regulatory biochemistry frequently impedes construction
of experimentally verifiable mathematical models.6 In con-
trast, computational frameworks that are relational (e.g.,
multilinear regression or partial least-squares regression) or
logical (e.g., Boolean logic or fuzzy logic) in nature have
shown the most powerful predictive capabilities across
physiologically diverse contexts despite experimental mea-
surement limitations.7 These frameworks provide input-
output “transfer function” models similar to PD modeling but
comprise many more variables, as required for a systems
perspective.8 Similar approaches are likely required to
understand the complex biology in MPS platforms, much
less predict in vivo responses from them.
Unfortunately, measurement types obtainable in vivo to
populate relational or logical PD models are much more
limited than in vitro. There might, however, be sufficient
Figure 1 Multi-MPS platforms will require mechanistic mathemat-
ical models for both on-platform scaling and in vitro-in vivo trans-
lation. The models for each are likely to have common elements,
while also being specialized for each intended use.
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measurements offering surrogate information suitable to
construct comparable input-output transfer function models
for translation between in vitro and in vivo, as evidenced by
equally valid alternative models for functional responses
based on different kinds of molecular data, including
mRNA, miRNA, protein, phosphoprotein, and protein activ-
ities.9 To discern key mechanisms of the invasive inflamma-
tory disease endometriosis, for example, experimental
measurements of cytokines, growth factors, and protease
activities from human patient peritoneal fluid samples have
been used in multivariate classification and network mod-
els.9,10 To study this disease in vitro, these cellular and
molecular properties could be similarly quantified in an
endometrium MPS and analogous models constructed;
translation between in vitro and in vivo models using
“transfer functions” is envisioned. Figure 2 illustrates the
idea of utilizing system models to capture and translate
between in vivo and in vitro systems based on measure-
ments feasible in both, buttressed by additional knowledge
enabled by superior measurement and manipulation capa-
bilities in vitro.
SUMMARY
Our perspective is that “scaling” of MPSs comprises more
than system specifications. Multivariate on-platform scaling
is critical to provide appropriate mechanistic interactions
within and between MPS units; however, relating observa-
tions from in vitro platforms to observations in the related in
vivo systems also requires translation using mathematical
models. Observations in vitro need not, and likely do not,
mimic those in vivo because of overwhelming uncertainty
about contextual variables and variation in living organisms.
However, insights gained from in vitro systems should be
translatable to insights into in vivo systems by means of
appropriate modeling relationships.
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